|
| 36635232 | Joint longitudinal and time-to-event modelling compared with standard Cox modelling in patients with type 2 diabetes with and without established cardiovascular disease: An analysis of the EXSCEL trial. | Diabetes Obes Metab | 2023 |
| 37075928 | Perspectives in weight control in diabetes - SGLT2 inhibitors and GLP-1-glucagon dual agonism. | Diabetes Res Clin Pract | 2023 |
| 34514692 | Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy. | Diabetes Obes Metab | 2022 |
| 32727288 | Melioidosis: distinctive clinico-epidemiological characteristics in southern India. | Trop Doct | 2021 |
| 33620762 | Long-term (52-week) efficacy and safety of dapagliflozin as an adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the DEPICT-2 study. | Diabetes Obes Metab | 2021 |
| 33690915 | Predicting major adverse limb events in individuals with type 2 diabetes: Insights from the EXSCEL trial. | Diabet Med | 2021 |
| 33499278 | Measuring Software Maintainability with Naïve Bayes Classifier. | Entropy (Basel) | 2021 |
| 34976533 | Simulated Randomized Controlled Trial to Learn Critical Appraisal (SiRCA): A Randomized Controlled Study of Effectiveness Among Undergraduate Medical Students. | Cureus | 2021 |
| 33145944 | Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52-week outcomes from the DEPICT-1 and -2 studies. | Diabetes Obes Metab | 2021 |
| 32311204 | Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial. | Diabetes Obes Metab | 2020 |
| 32098501 | Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes. | Circulation | 2020 |
| 33037036 | Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week results from the DURATION-NEO-1 study. | BMJ Open Diabetes Res Care | 2020 |
| 32946821 | Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials. | Lancet Diabetes Endocrinol | 2020 |
| 32691513 | Benefit/risk profile of dapagliflozin 5 mg in the DEPICT-1 and -2 trials in individuals with type 1 diabetes and body mass index â¿¥27â¿¿kg/m<sup>2</sup>. | Diabetes Obes Metab | 2020 |
| 30614411 | Diagnostic utility of bone marrow examination in evaluation of fever: a descriptive study on 98 immunocompetent adults from a tertiary care institute in south India. | Trop Doct | 2019 |
| 31490862 | Simulation-Based Training in Measurement of Blood Pressure: A Randomized Study of Impact in Real-Life Settings. | Simul Healthc | 2019 |
| 31542942 | Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial. | Circulation | 2019 |
| 31010875 | Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). | Diabetes Care | 2019 |
| 31077072 | Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials. | Diabetes Ther | 2019 |
| 30499237 | Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes. | Diabetes Obes Metab | 2019 |
| 30600137 | Efficacy and tolerability of exenatide once weekly over 7⿯years in patients with type 2 diabetes: An open-label extension of the DURATION-1 study. | J Diabetes Complications | 2019 |
| 28685973 | Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes. | Diabetes Obes Metab | 2018 |
| 29802530 | Characterization of the Open-Label Lead-In Period of Two Randomized Controlled Phase 3 Trials Evaluating Dapagliflozin, Saxagliptin, and Metformin in Type 2 Diabetes. | Diabetes Ther | 2018 |
| 30371301 | Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial. | J Am Heart Assoc | 2018 |
| 30571356 | Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients With Preexisting Cardiovascular Disease. | Circulation | 2018 |
| 29446523 | Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin. | Diabetes Obes Metab | 2018 |
| 29221659 | Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. | Lancet Diabetes Endocrinol | 2018 |
| 28857388 | Metformin extended-release versus immediate-release: An international, randomized, double-blind, head-to-head trial in pharmacotherapy-naïve patients with type 2 diabetes. | Diabetes Obes Metab | 2018 |
| 27849380 | COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION. | Endocr Pract | 2017 |
| 28454792 | Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). | Am Heart J | 2017 |
| 28181728 | Hypoglycaemia manifestations and recurrent events: Lessons from the SAVOR-TIMI 53 outcome study. | Diabetes Obes Metab | 2017 |
| 28205322 | Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study. | Diabetes Obes Metab | 2017 |
| 29132489 | Auto-Amputated Ovary Presenting as Abdominal Mass in an Infant. | J Coll Physicians Surg Pak | 2017 |
| 28910237 | Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. | N Engl J Med | 2017 |
| 28903775 | Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin. | Cardiovasc Diabetol | 2017 |
| 27797925 | Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial. | Diabetes Care | 2017 |
| 26995376 | Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. | Am Heart J | 2016 |
| 26385269 | Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA). | Diabetes Metab Res Rev | 2016 |
| 26623980 | Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade. | Blood Press | 2016 |
| 26620248 | Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. | Lancet Diabetes Endocrinol | 2016 |
| 26589253 | Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial. | J Diabetes | 2016 |
| 27385192 | Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52â¿¿weeks in patients with type 2 diabetes. | Diabetes Obes Metab | 2016 |
| 27525540 | Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study. | Diabetes Technol Ther | 2016 |
| 27413521 | Clinical and Laboratory Characteristics of Dengue-Orientia tsutsugamushi co-Infection from a Tertiary Care Center in South India. | Mediterr J Hematol Infect Dis | 2016 |
| 27222508 | Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial. | Diabetes Care | 2016 |
| 27403645 | One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin. | Diabetes Obes Metab | 2016 |
| 27402391 | Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes and Moderate Renal Impairment. | Diabetes Ther | 2016 |
| 26889668 | Selective association of electrocardiographic abnormalities with insulin sensitivity and beta-cell function in type 2 diabetes mellitus: a cross-sectional analysis. | Diabetes Metab Res Rev | 2016 |
| 25352655 | Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. | Diabetes Care | 2015 |
| 26576204 | Impact of focused training on communication skills of final-year medical students in a medical school in India. | Australas Med J | 2015 |